Product Name :
AER-271
Description:
AER-271, a phosphonate prodrug derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke.
CAS:
634913-39-6
Molecular Weight:
463.65
Formula:
C15H9ClF6NO5P
Chemical Name:
(2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenoxy)phosphonic acid
Smiles :
OP(O)(=O)OC1=CC=C(Cl)C=C1C(=O)NC1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F
InChiKey:
WSHXPHFIHYXZKC-UHFFFAOYSA-N
InChi :
InChI=1S/C15H9ClF6NO5P/c16-9-1-2-12(28-29(25,26)27)11(6-9)13(24)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6H,(H,23,24)(H2,25,26,27)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
AER-271, a phosphonate prodrug derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke.|Product information|CAS Number: 634913-39-6|Molecular Weight: 463.{{Tacrine} medchemexpress|{Tacrine} Neuronal Signaling|{Tacrine} Purity & Documentation|{Tacrine} In stock|{Tacrine} manufacturer|{Tacrine} Epigenetic Reader Domain} 65|Formula: C15H9ClF6NO5P|Chemical Name: (2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenoxy)phosphonic acid|Smiles: OP(O)(=O)OC1=CC=C(Cl)C=C1C(=O)NC1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F|InChiKey: WSHXPHFIHYXZKC-UHFFFAOYSA-N|InChi: InChI=1S/C15H9ClF6NO5P/c16-9-1-2-12(28-29(25,26)27)11(6-9)13(24)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6H,(H,23,24)(H2,25,26,27)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (269.{{Ixazomib} MedChemExpress|{Ixazomib} Proteasome|{Ixazomib} Biological Activity|{Ixazomib} Formula|{Ixazomib} supplier|{Ixazomib} Epigenetic Reader Domain} 60 mM; Need ultrasonic).PMID:33272106 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke.|Products are for research use only. Not for human use.|